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Abstract  
Our previous studies demonstrated that cycleanine, a macrocyclic bisbenzylisoquinoline 
(BBIQ) alkaloid, showed potent anti-ovarian cancer activity via apoptosis induction. 
Here, we synthesized two novel (aminoalkyl)cycleanine analogues (2 and 3) through a 
simple and efficient two-step reaction starting from cycleanine isolated from Triclisia 
subcordata Oliv.. These analogues showed greater potency than the unmodified 
cycleanine in three human ovarian cancer cell lines. Both 2 and 3 induced apoptosis in 
ovarian cancer cells by activations of caspases 3/7, cleavage of PARP, increase in 
subG1 cell cycle phase and in the percentage of apoptotic cells. Further confocal 
fluorescence microscopy analysis confirmed the cellular uptake of alkaloids in ovarian 
cancer cells by using the unique alknylcycleanine (3) via click chemistry reaction. Our 
results suggest that cycleanine could be a hit compound for the future development in 
attacking ovarian cancer.   
 
Keywords: Cycleanine; bisbenzylisoquinoline alkaloid; ovarian cancer; semi-synthesis; 
cellular uptake; apoptosis 
  
3 
 
The macrocyclic bisbenzylisoquinoline (BBIQ) alkaloids are among different large 
classes of alkaloids common in plant species. BBIQ alkaloids are prevalent in the 
families like Menispermeaceae, Annonaceae, Berberidaceae, Monimaiaceae and 
Ranunuclaceae.1-3 The BBIQ alkaloids were reported to exhibit anti-ovarian,4-7 –lung,8 –
bladder,9 –colorectal,10 -gallbladder carcinoma and –prostate11 cancer activities.12, 13 
The use of isolated natural products as scaffolds to generate their analogues via 
chemical transformation is a promising and successful approach in drug discovery.14, 15 
So far, only a small number of semi-synthetic BBIQ alkaloids (e.g. tetrandrine and 
fanginoline analogues,16-19 C14-urea-tetrandrine,20 cycleanine mono-N-oxides,21 and 
berbamine derivatives.22) have been made, which show potent cytotoxicity or can 
reverse P-glycoprotein-mediated multidrug resistance in cancer cells17, 23. The making 
of more potent cytotoxic BBIQ alkaloids with improved activities and investigation of 
their mechanisms of action (e.g. cellular uptake, target identification) by using the 
synthetic probes are desired. 24, 25 Previously, several BBIQ alkaloids were isolated from 
Triclisia subcordata Oliv. by us and they showed potent in vitro anti-ovarian cancer 
activity.4-6 Among them, cycleanine (1) is bioactive, with the highest therapeutic index 
and the most abundant component (1.1%).4 Therefore cycleanine was preferred as a hit 
compound for chemical modification.14 In this study, we semi-synthesized analogues of 
cycleanine and evaluated their cytotoxicity, induction of apoptosis, and cellular uptake. 
The semi-synthesis of cycleanine analogues was achieved via a simple two-step 
reaction (Scheme 1). Reaction of cycleanine (1) under paraformaldehyde and 
concentrated HCl produced the intermediate 5-chloromethylcycleanine through a Blanc 
chloromethylation reaction.26  Without purification 5-chloromethylcycleanine reacted with 
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dimethylamine and propargylamine via SN2 nucleophilic substitution reaction to yield 5-
[(dimethylamino)methyl]cycleanine (2), and 5-[(propargylamino)methyl]cycleanine (3), 
respectively  (Supporting information).  
 
Scheme 1. Semi-synthesis of (aminoalkyl)cycleanine analogues via modification of 
cycleanine.   
Reagents and conditions: (a) paraformaldehyde, conc. HCl, 0 °C, 3h;  (b) CH3CN, 
NaOH, dimethylamine or propargylamine,  rt, 3h. 
 
Compounds 2 and 3 were purified by silica gel chromatography to a high purity (>98%) 
as determined by analytical high performance liquid chromatography. The structure of 
5-[(dimethylamino)methyl]cycleanine (2) and 5-[(propargylamino)methyl]cycleanine  (3)  
was confirmed on the  basis of 1H NMR (Table S1, Figure S1 and S2), 13C NMR (Table 
S2), 2D NMR and high resolution liquid chromatography mass spectrometric (LC-MS) 
analysis. The symmetry of cycleanine was lost after the chemical modification, as 
evidenced by that the single peak for H-5 or 5' in the 1H NMR of cycleanine4 was shifted 
and other peaks for aromatic protons were split into two pairs of peaks (Table S1, 
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Figure S1 and S2). The resulting single peak around 6.80 ppm in the 1H NMR of 2 or 3 
corresponds to only one proton (H-5') which indicates the substitution at C-5 of 
cycleanine (1) by the alkylamino groups. The addition of aminoalkyl group to cycleanine 
could improve its water solubility as found in the approved anticancer drug such as 
(aminoalkyl)camptothecin (Toptecan).27, 28 
To assay the cytotoxicity or anti-proliferative activities of 2 and 3, the IC50 of these new 
compounds were evaluated on different ovarian cancer cell lines (OVCAR-8, A2780 and 
IGROV-1) and a normal human ovarian epithelial (HOE) cell line after treatment for 72h 
using Sulforhodamine B (SRB) colorimetric assay.29, 30 The results reveal the IC50 of 2 
and 3 ranging from 3.6 ± 0.5 to 5.2 ± 0.6 µM and from 5.6 ± 0.2 to 6.3 ± 0.6 µM, 
respectively (Table 1; Figures S3 and S4). The results suggest that 2 and 3, exert about 
2-3 times improved potency against three ovarian cancer cells than cycleanine (1) with 
IC50 ranging from 7 to 14 µM and the approved anti-ovarian cancer drug-carboplatin 
with IC50 ranging from 8 to 16 µM. Cycleanine (1) and 3 seem to be slightly more 
tolerant to HOE cells than compound 2. Overall, compound 3 showed milder selectivity 
index (SI) than 1 and 2 (Table 1). 
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Table 1 The IC50 of cycleanine (1), 5-[(dimethylamino)methyl]cycleanine (2) and 5-
[(propargylamino) methyl]cycleanine  (3) in ovarian cancer cells. Data represented as 
mean ± SEM (n= 5).  SI means selective index. 
 
The effects of 2 and 3 on morphology of OVCAR-8 cancer cells were also found to be 
time- and concentration-dependent (Figure S5 and S6). Both of them caused the 
shrinkage of the cell, cell detachment, and the nucleus condensation, which are 
characteristic features of apoptosis of cells. The induction of apoptosis in cancer cells 
by 2 and 3 was further investigated by evaluation of caspase 3/7 activation, cleavage of 
PARP, flow cytometry, and cell cycle assays.  
2 and 3 after exposure to OVCAR-8, A2780 and IGROV-1 for 24h caused activation of 
caspase Glo 3/7 activities, which was manifested as elevation of caspase levels (Figure 
1). 
                         
Compound 
Ovarian cancer cell lines (µM) HOE (µM) 
OVCAR-8 A2780 IGROV-1 
     
1 10 ± 0.6 7.6 ± 0.7 14 ± 1.0 35 ± 1.0 
SI (1) 3 5 3  
2 5.2 ± 0.6 
 
3.6 ± 0.5 
 
4.4 ± 0.1 10 ± 0.2 
SI (2) 2 
 
3 2  
3 5.6 ± 0.2 
 
6.3 ± 0.6 
 
6.1 ± 0.5 
 
32 ± 1.6 
SI (3) 
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5 5  
Carboplatin                       16 ± 1.0  8.0 ± 0.7 12 ± 0.9 - 
7 
 
 
Figure 1 The apoptotic effects (increase of caspase 3/7 activities) of carboplatin, 5-
[(dimethylamino)] cycleanine (2) and 5-[(propargylamino) methyl] cycleanine (3) on 
three ovarian cancer cell lines. Data represented as mean ± SEM, n=6 observations, 
negative control was the DMSO (0.2%), carboplatin used as positive control, 2 and 3 
(20 μM). Results were significant compared to control (*** P<0.005, one-way ANOVA) 
post hoc analysis multiple t-test compared with control (**P<0.01, *** P<0.001).  
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Figure 2 Western blotting analysis of the PARP-1 cleavage (apoptosis marker) in 
OVCAR-8 cells after treatment with carboplatin, 5-[(dimethylamino)methyl]cycleanine 
(2) and 5-[(propargylamino)methyl]cycleanine  (3). GAPDH was used as a loading 
control. A representative of three independent experiments is shown.  
 
Western blotting results showed that OVCAR-8 cancer cells by treatment of 2 and 3 
caused a significant cleavage of PARP to produce PARP-1 fragment (Figure 2) in a 
similar way as cycleanine4. There was no significant PARP-cleavage observed in 
negative control. 
For quantification of the percentage of apoptotic cells post-treatment with 2 and 3, 
OVCAR-8 cells were treated and stained with both Annexin V-FITC and propidium 
iodide (PI) and analysed by flow cytometry. Treatment of OVCAR-8 with carboplatin, 2 
and 3 over 48h caused significant increase in the population of both early and late 
apoptotic cells compared to the control cells (Figure 3). 
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Figure 3 Flow cytometry analysis of apoptotic effects of 5-
[(dimethylamino)methyl]cycleanine (2) and 5-[(propargylamino)methyl]cycleanine  (3)  
on OVCAR-8 cells. The scattering dot plots indicating the percentage of live, early and 
late apoptotic cells under treatment of medium (control) (A), carboplatin (B), compound 
2 (C), and compound 3 (D) (20 μM) for 48 hours by using Annexin V-FITC  & PI assay. 
The percentages of the total apoptotic cells (E) caused by 2, 3 and carboplatin (positive 
control) were significant compared to negative control (one way ANOVA for group 
analysis, P<0.001; post hoc paired t-test relative to control was done (* P<0.05)). 
The effect on cell cycle by 2 and 3 in OVCAR-8 cells was analysed using PI and flow 
cytometry. The percentage of OVCAR-8 cells in subG1 increased after exposure to 
carboplatin, 2 and 3 for 48h compared to negative control. The percentage of cells at 
the G0/G1 phase (live cells) decreased significantly compared to control (Figure 4). This 
was similar to result of cycleanine as reported previously4. 
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Figure 4 Cell cycle distribution analysis of apoptotic effects of 5-
[(dimethylamino)methyl]cycleanine (2) and 5- [(propargylamino)methyl]cycleanine (3) on 
OVCAR-8 cell lines. Data represented as mean ± SEM, n = 4 observations. The 
percentage of subG1 phase (apoptotic cells) of the OVCAR-8 cell cycle was significantly 
increased compared to cells exposed to control, while the percentage of G0/G1 phase 
cells decreased significantly compared to control (P< 0.001, one-way ANOVA). 
Because compound 3 with modification of a propargyl group showed similar potency 
and induction of apoptosis as cycleanine (1), it was used as a model compound to 
investigate the cellular uptake of BBIQ alkaloids. Therefore medium (control), 
cycleanine (1) and 3 were administered in OVCAR-8 cells for 48h. Alexa 488 azide (a 
fluorescent dye) was used to monitor the intracellular uptake of 5-
[(propargylamino)methyl]cycleanine  (3)  via specific click chemistry reaction25. 
Cycleanine is not fluorescent compound. The cells of control and after treatment of 
cycleanine showed little fluorescence (Figure 5A and B), while the cells treated by 3 
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showed very strong fluorescence (Figure 5C). The fluorescence intensity was used as a 
measure of the distribution and uptake of 3 in OVCAR-8 cells. Treatment with 3 caused 
dramatic increase in mean fluorescence intensities (Figure 5D) compared to control 
cells. There was no significant change in fluorescence intensity observed in cycleanine-
treated cells compared to control (Figure 5D), because they both lack an alkynyl group 
which is necessary for the click chemistry reaction with Alexa 488 azide dye. Only 3 
reacted with Alexa 488 azide dye, thus causing the intense fluorescence. Increase of 
concentration of 3 indicated the increase of fluorescence (Figure S7). These results 
confirmed the intracellular uptake of cycleanine derivative (3). 
 
Figure 5 Analysis intracellular uptake of cycleanine (1) and 5-
[(propargylamino)methyl]cycleanine (3) in OVCAR-8 cells using confocal fluorescence 
microscopy. Graph A, B and C represents cell images after treatment with medium only 
(control), cycleanine, and 3 (each 20 µM), respectively. D represents for the mean 
fluorescence intensity of OVCAR-8 cells after 48h treatment. The fluorescence data 
were analyzed by the determination of the average fluorescence intensities of the cells 
in an area by use of Image J software and evaluation of the difference from the 
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background fluorescence values. Values were evaluated from 30-90 cells determined in 
five independent experiments. Data represented as mean ± SEM, n = 5 independent 
experiments. Results were significant compared to control (*** P<0.0001, one-way 
ANOVA)). 
In summary, we have successfully semi-synthesized two novel aminoalkyl BBIQ 
alkaloids (2 and 3) starting from an isolated natural product-cycleanine through a simple 
and efficient method of site-specific chemical modification at C-5 position of cycleanine. 
The new modification approach has advantages over some reported transformation 
methods for BBIQ alkaloids.16, 17, 21 Because it can be applied to cycleanine as well as 
other BBIQ alkaloids to make a large number of analogues using a range of other 
nucleophilic compounds (e.g. primary and secondary amines, thiols). Furthermore, the 
available alkynylcycleanine (3) could react with any azide-containing 
compounds/anticancer drugs such as platinum derivatives to generate dual BBIQ 
alkaloid and platinum conjugates via click chemistry,31 which may produce potentially 
stronger synergic effects between them32. The observed anti-proliferative activities and 
selectivity (Table 1) of the semi-synthetic BBIQ alkaloids were found to be higher (about 
2-3-fold increase) than the observed effect with cycleanine (a hit compound). This 
suggests that substitution at 5-position of cycleanine with a dimethylaminoalkyl or an 
alkynylaminoalkyl group could lead to improved cytotoxicity of cycleanine. The 
mechanism of cancer cell death induced by the new BBIQ alkaloids has been 
determined as apoptosis induction by caspase 3/7 activation, PARP-cleavage, increase 
in percentage of both early and late apoptotic cells; and increase in SubG1 with 
decrease in G0/G1 cell cycle phase of the OVCAR-8 cells. These were consistent with 
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unmodified cycleanine and other BBIQ alkaloids.4, 5 Importantly, using analogue 3 
appended with a propargyl group its cellular uptake in cancer cells was clearly 
demonstrated via click chemistry and fluorescence microscopy. The semi-synthesis of 
additional BBIQ alkaloid analogues using the established approach to gain structure-
activity relationship, and identification of protein targets in the cancer cells using a 
chemical proteomics approach33, 34 are ongoing in our laboratory. In vivo studies also 
need to be performed to evaluate the preclinical and clinical effects of these novel 
compounds. 
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